SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

PINOTTI, Mirko
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.073
AS - Asia 8.421
EU - Europa 5.012
SA - Sud America 1.328
AF - Africa 142
OC - Oceania 17
Continente sconosciuto - Info sul continente non disponibili 7
AN - Antartide 1
Totale 32.001
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.720
SG - Singapore 3.398
CN - Cina 2.469
BR - Brasile 1.116
IT - Italia 1.061
DE - Germania 1.056
UA - Ucraina 764
HK - Hong Kong 761
VN - Vietnam 528
TR - Turchia 505
GB - Regno Unito 501
FI - Finlandia 343
PL - Polonia 287
RU - Federazione Russa 243
SE - Svezia 205
ID - Indonesia 186
CA - Canada 171
MX - Messico 157
FR - Francia 144
IN - India 135
AR - Argentina 94
JP - Giappone 81
BE - Belgio 79
BD - Bangladesh 76
ZA - Sudafrica 74
NL - Olanda 70
ES - Italia 61
IQ - Iraq 44
EC - Ecuador 38
CZ - Repubblica Ceca 36
AT - Austria 32
UZ - Uzbekistan 31
LT - Lituania 21
IR - Iran 20
KE - Kenya 18
PK - Pakistan 18
VE - Venezuela 18
CO - Colombia 17
CH - Svizzera 16
KR - Corea 16
IL - Israele 15
MA - Marocco 15
MY - Malesia 15
PT - Portogallo 15
AU - Australia 13
JO - Giordania 13
RO - Romania 13
AE - Emirati Arabi Uniti 12
GE - Georgia 12
PE - Perù 12
PY - Paraguay 12
DK - Danimarca 11
NO - Norvegia 11
KZ - Kazakistan 10
SA - Arabia Saudita 10
AZ - Azerbaigian 9
TW - Taiwan 9
IE - Irlanda 8
UY - Uruguay 8
AL - Albania 7
CL - Cile 7
CR - Costa Rica 7
DZ - Algeria 6
TN - Tunisia 6
KG - Kirghizistan 5
NP - Nepal 5
SN - Senegal 5
TH - Thailandia 5
BG - Bulgaria 4
BO - Bolivia 4
BY - Bielorussia 4
LA - Repubblica Popolare Democratica del Laos 4
LU - Lussemburgo 4
NG - Nigeria 4
OM - Oman 4
AF - Afghanistan, Repubblica islamica di 3
DO - Repubblica Dominicana 3
EG - Egitto 3
EU - Europa 3
GA - Gabon 3
GT - Guatemala 3
KH - Cambogia 3
KW - Kuwait 3
LB - Libano 3
NI - Nicaragua 3
NZ - Nuova Zelanda 3
QA - Qatar 3
RS - Serbia 3
XK - ???statistics.table.value.countryCode.XK??? 3
BH - Bahrain 2
BW - Botswana 2
CG - Congo 2
GR - Grecia 2
HN - Honduras 2
HU - Ungheria 2
LK - Sri Lanka 2
LV - Lettonia 2
PA - Panama 2
PH - Filippine 2
A2 - ???statistics.table.value.countryCode.A2??? 1
Totale 31.977
Salva come PNG Salva come JPEG
Città #
Singapore 1.939
Ashburn 1.546
Fairfield 1.429
Woodbridge 1.423
Dallas 1.260
Chandler 991
Houston 951
Santa Clara 917
Beijing 846
Jacksonville 814
Hong Kong 746
Ann Arbor 719
Seattle 614
Wilmington 557
Cambridge 474
Ferrara 393
Munich 317
New York 308
Izmir 307
Los Angeles 296
Warsaw 278
Nanjing 256
Princeton 232
Ho Chi Minh City 178
Boardman 162
Shanghai 155
Milan 149
Jakarta 146
Helsinki 139
San Diego 133
Hanoi 113
São Paulo 113
Dearborn 109
Bremen 105
Mexico City 100
Nanchang 84
Shenyang 73
Brussels 71
London 71
Tianjin 68
Brooklyn 63
Tokyo 61
Falls Church 60
Montreal 59
Toronto 59
Jiaxing 57
The Dalles 56
Orem 55
Redwood City 54
Hefei 51
Chicago 50
Denver 50
Changsha 49
Moscow 48
Atlanta 47
Buffalo 47
Johannesburg 47
Hebei 45
Poplar 43
Jinan 42
Frankfurt am Main 41
Rio de Janeiro 41
Chennai 40
Turku 39
Stockholm 38
San Mateo 37
Falkenstein 36
Mountain View 35
Phoenix 35
Bologna 34
Dong Ket 33
Guangzhou 32
Kunming 30
Norwalk 30
Curitiba 29
Nuremberg 29
Des Moines 28
Belo Horizonte 27
San Francisco 26
San Jose 26
Tashkent 25
Auburn Hills 24
Manchester 24
Ningbo 24
Zhengzhou 24
Ankara 23
Brno 23
Columbus 23
Da Nang 22
Campinas 21
Padova 20
Porto Alegre 20
Washington 19
Amsterdam 18
Baghdad 18
Boston 18
Brasília 18
Querétaro 18
Orange 17
Paris 17
Totale 21.707
Salva come PNG Salva come JPEG
Nome #
1,3,8-Triazaspiro[4.5]decane Derivatives Inhibit Permeability Transition Pores through a FO-ATP Synthase c Subunit Glu119-Independent Mechanism That Prevents Oligomycin A-Related Side Effects 952
Differential functional readthrough over homozygous nonsense mutations contributes to the bleeding phenotype in coagulation factor VII deficiency 265
AN EXON-SPECIFIC U1 SMALL NUCLEAR RNA (snRNA) STRATEGY TO CORRECT SPLICING MUTATIONS ASSOCIATED TO HEMOPHILIA B 263
Regulation of a strong F9 cryptic 5'ss by intrinsic elements and by combination of tailored U1snRNAs with antisense oligonucleotides 252
An engineered tale-transcription factor rescues transcription of factor VII impaired by promoter mutations and enhances its endogenous expression in hepatocytes 250
An exon-specific U1snRNA induces a robust factor IX activity in mice expressing multiple human FIX splicing mutants 247
Exploring Splicing-Switching Molecules For Seckel Syndrome Therapy 242
Akt-mediated phosphorylation of MICU1 regulates mitochondrial Ca 2+ levels and tumor growth 240
Fo ATP synthase C subunit serum levels in patients with ST-segment Elevation Myocardial Infarction: Preliminary findings 234
A frequent human coagulation Factor VII mutation (A294V, c152) in loop 140s affects the interaction with activators, tissue factor and substrates 217
Stimulation of P2 (P2X7) receptors in human dendritic cells induces the release of tissue factor-bearing microparticles. 211
Molecular Basis and Therapeutic Strategies to Rescue Factor IX Variants That Affect Splicing and Protein Function 211
U1-snRNA-mediated rescue of mRNA processing in severe factor VII deficiency 209
Responsiveness of hemophilia B- causing non sense mutations to ribosome readthrough-inducing drugs strictly depends on the nucleotide and prrotein context 207
Activation of a cryptic splice site in a potentially lethal coagulation defect accounts for a functional protein variant 203
VITAMIN K-INDUCED MODIFICATION OF COAGULATION PHENOTYPE IN VKORC1 HOMOZYGOUS DEFICIENCY 202
Nuove strategie per la veicolazione di acidi nucleici: nanosistemi cationici a matrice lipidica 202
U1snRNA-mediated rescue of mRNA processing in severe factor VII deficiency 198
Factor XIII-A dynamics in acute myocardial infarction: a novel prognostic biomarker? 197
Attività sulla emostasi di alcune piante della medicina tradizionale indiana 194
Chronic sleep deprivation markedly reduces coagulation factor VII expression 194
Cationic lipid nanosystems as carriers for nucleic acids 194
Transposon-mediated Generation of Cellular and Mouse Models of Splicing Mutations to Assess the Efficacy of snRNA-based Therapeutics 194
An exon-specific U1 small nuclear RNA (snRNA) strategy to correct splicing defects 191
An Altered Splicing Registry Explains the Differential ExSpeU1-Mediated Rescue of Splicing Mutations Causing Haemophilia A 191
Mcl-1 involvement in mitochondrial dynamics is associated with apoptotic cell death 189
Asymptomatic carriership of factor V Leiden and genotypes of the fibrinogen gene cluster 188
Polymorphisms at LDLR locus may be associated with coronary artery disease through modulation of coagulation factor VIII activity and independently from lipid profile 188
Mutation pattern in clinically asymptomatic coagulation factor VII deficiency 188
The carboxyl-terminal region is NOT essential for secreted and functional levels of coagulation factor X 184
Tailoring the CRISPR system to transactivate coagulation gene promoters in normal and mutated contexts 184
Effective hemostasis during minor surgery in a case of hereditary combined deficiency of vitamin K-dependent clotting factors 183
Molecular bases of type II protein S deficiency: the I203-D204 deletion in the EGF4 domain alters GLA domain function 182
Specific factor IX mRNA and protein features favor drug-induced readthrough over recurrent nonsense mutations 182
Membrane binding and anticoagulant properties of protein S natural variants 180
A unique exon specific U1snRNA rescues different haemophilia B - causing splicing-defective factor IX variants in mice 180
The carboxyl-terminal region is not essential for secreted and functional levels of coagulation factor X 180
Evidence for an overlapping role of clock and npas2 transcription factors in liver circadian oscillators 179
Daily and circadian rhythms of tissue factor pathway inhibitor and factor VII activity 178
FXIII levels and genotypes in myocardial infarction: a potential novel prognostic biomarker? 176
The chaperone-like sodium phenylbutyrate improves factor IX intracellular trafficking and activity impaired by the frequent p.R294Q mutation 176
Molecular bases of CRM+ factor X deficiency: a frequent mutation (Ser334Pro) in the catalytic domain and a substitution (Glul02Lys) in the second EGF‐like domain 175
The dominant-negative von Willebrand factor gene deletion p.P1127-C1948delinsR: Molecular mechanism and modulation 175
Influence of polymorphisms in the factor VII gene promoter on activated factor VII levels and on the risk of myocardial infarction in advanced coronary atherosclerosis 172
The factor V Glu1608Lys mutation is recurrent in familial thrombophilia 172
Missense changes in the catalytic domain of coagulation factor X account for minimal function preventing a perinatal lethal condition 172
Ribosome readthrough accounts for secreted full-length factor IX in hemophilia B patients with nonsense mutations 171
Cationic lipid nanosystems as carriers for nucleic acids 170
Natural and engineered carboxy-terminal variants: decreased secretion and gain-of-function result in asymptomatic coagulation factor VII deficiency 169
Circadian rhythms in mouse blood coagulation 168
Temporal variations of coagulation factor VII activity in mice are influenced by lighting regime 166
Variation of factor VII 140s and 170s loops in fishes: evolutionary aspects and comparison with mutations found in FVII deficiency 166
Residual factor VII activity and different hemorrhagic phenotypes in CRM+ factor VII deficiencies (Gly331Ser and Gly283Ser) 166
Exon-specific U1 snRNAs improve ELP1 exon 20 definition and rescue ELP1 protein expression in a familial dysautonomia mouse model 166
Altered mRNA processing and FVIII biosynthesis/function as determinants of phenotype variability in the frequent Arg2016Trp Haemophilia A patients. 165
Asymmetric processing of mutant factor X Arg386Cys reveals differences between intrinsic and extrinsic pathway activation 165
A naturally occurring mutation in ATP synthase subunit c is associated with increased damage following hypoxia/reoxygenation in STEMI patients 165
Correction of aberrant splicing causing haemophilia B through the combination of compensatory U1snRNAs and antisense oligonucleotides 163
Factor VII mutant V154G models a zymogen-like form of factor VIIa 161
Characterization of anti-coagulant properties of prenylated coumarin ferulenol. 158
The complete impairment of factor VII gene expression by the IVS6+1g/t mutation is compatible with a severe but not lethal bleeding disorder 157
Characterization of the intracellular signalling capacity of natural FXa mutants with reduced pro-coagulant activity 157
Aberrant splicing reverts a potentially lethal coagulation deficiency caused by a +1g/t splicing mutation 156
Molecular defects in CRM+ factor VII deficiencies: modelling of missense mutations in the catalytic domain of FVII 156
Replacement of the Y450 (c234) phenyl ring in the carboxyl-terminal region of coagulation factor IX causes pleiotropic effects on secretion and enzyme activity 155
Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease 154
Nanosistemi lipidici per la veicolazione di acidi nucleici 154
Acute Coronaric Syndroms and FVII polymorphisms: different effects in the same gene 154
Secretion of wild-type factor IX upon readthrough over F9 pre-peptide nonsense mutations causing hemophilia B 154
Molecular mechanisms of FVII deficiency: Expression of mutations clustered in the IVS7 donor splice site of factor VII gene 153
Combined effect of hemostatic gene polymorphisms and the risk of myocardial infarction in patients with advanced coronary atherosclerosis 153
Secretion of wild-type factor IX upon readthrough over F9 pre-peptide nonsense mutations causing hemophilia B 153
Modulation of factor VII levels by intron 7 polymorphisms: Population and in vitro studies 152
A strategy with chaperone-like compounds to restore expression of factor IX variants affected by frequent missense mutations causing hemophilia B 151
Disease-causing variants of the conserved+2T of 5 ' splice sites can be rescued by engineered U1snRNAs 149
A very rare simultaneous presence of a ring chromosome 13 and a splicing site mutation on Factor X gene 148
Activation of Endoplasmic Reticulum Stress and Unfolded Protein Response in Congenital Factor VII Deficiency 147
Detection of new polymorphic markers in the factor V gene: Association with factor V levels in plasma 146
Long-chain cationic derivatives of PTA (1,3,5-triaza-7-phosphaadamantane) as new components of potential non-viral vectors 146
Rescue of coagulation factor VII function by the U1+5A snRNA 145
Rescue of missense and splicing mutations in Haemophilia A by a unique Exon Specific U1snRNA 144
Impaired prothrombinase activity of factor X Gly381 Asp results in severe familial CRM+ FX deficiency 143
Next-generation sequencing and recombinant expression characterized aberrant splicing mechanisms and provided correction strategies in factor VII deficiency 143
Detection and characterization of polymorphic markers in the factor-VII gene. 142
The carboxyl-terminal region of human coagulation factor X as a natural linker for fusion strategies 142
Association of the homozygous nonsense mutation R402X in coagulation factor VII with asymptomatic phenotype 142
Non-conventional therapeutic strategies for inherited disorders oh hemostasis 140
CRISPR activation on coagulation F7 or F8 promoters potentiate trascriptional activity in the normal and mutated gene context 140
The carboxyl-terminal region of human coagulation factor X as a novel naturally-occuring linker for fusion strategies 140
Cationic nanostructured lipid carrier (NLC) and monoolein aqueous dispersions (MAD) as potential carriers for nucleic acids 139
RNA-based therapeutic approaches for coagulation factor deficiencies 139
Rescue of spinal muscular atrophy mouse models with AAV9-Exon-specific U1 snRNA 139
Contribution of factor VII genotype to activated FVII levels: Differences in genotype frequencies between northern and southern European populations 138
FXIII Levels in Myocardial Infarction: a Potential Novel Prognostic Biomarker? 138
The somatic FAH C.1061C>A change counteracts the frequent FAH c.1062+5G>A mutation and permits U1snRNA-based splicing correction 138
Management of Kidney Transplantation in a Factor VII-Deficient Patient: Case Report 138
An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics 138
The Gly331Ser mutation in factor VII in Europe and the Middle East 137
Polymorphic changes in the 5' flanking region of factor VII have a combined effect on promoter strength 137
Gentamicin induces sub-therapeutic levels of coagulation factor VII in patients with nonsense mutations 137
Totale 18.096
Salva come PNG Salva come JPEG
Categoria #
all - tutte 154.450
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.094
Totale 155.544
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.901 0 0 0 0 0 242 231 330 131 454 366 147
2021/20222.248 137 262 114 73 113 104 112 106 80 187 185 775
2022/20232.359 261 184 73 301 409 315 135 179 276 15 128 83
2023/20241.269 110 140 79 45 79 210 50 77 36 48 40 355
2024/20255.698 175 117 507 179 696 710 172 233 886 585 781 657
2025/20269.670 1.530 905 1.944 2.153 2.378 760 0 0 0 0 0 0
Totale 32.500